Radiation Response Modulation of GW572016 (EGFR/HER2 Dual Tyrosine Kinase Inhibitor) in Human Breast Cancer Xenografts.
- Author:
Yeon Sil KIM
1
;
Kwang Won ROH
;
Soo Min CHAE
;
Seong Kwon MUN
;
Sei Chul YOON
;
Hong Seok JANG
;
Su Mi CHUNG
Author Information
1. Department of Radiation Oncology, The Catholic University of Korea, College of Medicine, Seoul, Korea. yeonkim7@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
EGFR;
HER2;
Dual tyrosine kinase inhibitor;
Radiosensitization
- MeSH:
Animals;
Arm;
Blotting, Western;
Breast Neoplasms*;
Breast*;
Cell Line;
Heterografts*;
Humans*;
Immunoprecipitation;
Mice;
Mice, SCID;
Phosphorylation;
Protein-Tyrosine Kinases*;
Radiotherapy;
Tyrosine*
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2007;25(4):233-241
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We examined the effect of the dual EGFR/HER2 tyrosine kinase inhibitor, GW572016, on EGFR/HER2 receptor phosphorylation, inhibition of downstream signaling and radiosensitization in either an EGFR or HER2 overexpressing human breast cancer xenograft. MATERIALS AND METHODS: We established SCID mice xenografts from 4 human breast cancer cell line that overexpressed EGFR or HER 2 (SUM 102, SUM 149, SUM 185, SUM 225). Two series of xenografts were established. One series was established for determining inhibition of the EGFR/HER2 receptor and downstream signaling activities by GW572016. The other series was established for determining the radiosensitization effect of GW572016. Inhibition of the receptor and downstream signaling proteins were measured by the use of immunoprecipitation and Western blotting. For determining the in vivo radiosensitization effect of GW572016, we compared tumor growth delay curves in the following four treatment arms: a) control; b) GW572016 alone; c) radiotherapy (RT) alone; d) GW572016 and RT. RESULTS: GW572016 inhibited EGFR, HER2 receptor phosphorylation in SUM 149 and SUM 185 xenografts. In addition, the p44/42 MAPK (ERK 1/2) downstream signaling pathway was inactivated by GW572016 in the SUM 185 xenograft. In the SUM 225 xenograft, we could not observe inhibition of HER2 receptor phosphorylation by GW572016; both p44/42 MAPK (Erk1/2) and Akt downstream signal protein phosphorylation were inhibited by GW572016. GW572016 inhibited growth of the tumor xenograft of SUM 149 and SUM 185. The combination of GW572016 and RT enhanced growth inhibition greater than that with GW572016 alone or with RT alone in the SUM 149 xenograft. GW572016 appears to act as an in vivo radiosensitizer. CONCLUSION: GW572016 inhibited EGFR/HER2 receptor phosphorylation and downstream signaling pathway proteins. GW572016 modestly inhibited the growth of tumor in the SUM 185 xenograft and showed radiosensitization in the SUM 149 xenograft. Our results suggest that a better predictor of radiation response would be inhibition of a crucial signaling pathway than inhibition of a receptor.
